Arriving at a critical point for field, the Non-Small Cell Lung Cancer Drug Development Summit will enable attendees to see a full picture of the clinical trial landscape and identify what MoAs and targets future biopharma investment will be put towards.
Taking place online this July 13-15, this is the first conference to bring drug development teams together to address critical challenges surrounding therapeutic potency, tumor resistance and relapse and expanding the clinical utility of targeted and immuno-therapies, either in combination or monotherapies.
The new agenda has now been revealed: View the Full Event Guide Here.
29+ Expert Speakers
The 3-day, insight-driven agenda will feature hand-picked industry experts, including:
- Emmett V. Schmidt, Vice President, Clinical Research Lead, External Collaborations Oncology Early Development, Merck & Co
- Serban Ghiorghiu, Head of Clinical, Late Development Oncology R&D, AstraZeneca & European Commission’s Mission for Cancer, Board Member
- Tony Jarkowski, Development Lead, Bristol Myers Squibb
- Cecile Geuijen, Vice President Oncology – Cell Biology, Merus
- Mike Humphries, US Scientific Director – Lung Cancer, Takeda Oncology
- Rachel Humphrey, Chief Medical Officer, Black Diamond Therapeutics
The agenda has also been designed with built-in speaker Q & A session so that attendees will have ample opportunity to get their questions answered first-hand.
View the full speaker list here.
The Ultimate Guide
Dedicated to accelerating clinical translation of novel therapies and optimizing best-in-class approaches, the meeting promises unrivalled content covering all major targeted drug and immuno-oncology clinical investigations for the largest global unmet clinical need in solid tumor indications.
Topics to be covered include:
- Recent advancements in targeting therapy & immunotherapy in the treatment of advanced NSCLC
- Generations of progress in targeting EGFR through TKIs
- Targeting mutation & overexpression in EGFR
- Targeting the MET oncogene in NSCLC
- Targeting PI3K & associated pathways to address resistance
- Drugging the undruggable KRAS mutation in NSCLC
- Immunotherapy strategy for NSCLC
- Targeting rare mutations in NSCLC
- Optimizing precision oncology, treatment regimes & administration to improve patient outlook
40+ Attendees Confirmed – And Counting!
In just a few short weeks over 40 attendees have confirmed their places at the meeting.
They include Abbvie, Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Elevation Oncology, Immutep, Iterion Therapeutics, Maverick Therapeutics, Merck, Novartis, Takeda Oncology and many more.
The meeting offers earlybird rates as well as additional group discounts.
Register online now for the best possible rates.
“The Non-Small Cell Lung Cancer Summit will be an important venue to learn more about the latest developments in lung cancer, including the emerging new treatments, and some of the informative new science.”
Tony Jarkowski, Development Lead, Bristol Myers- Squibb
Find Out More:
View the full event guide here for more details about the speakers, agenda, digital platform and pricing.
Alternatively, contact the team using the details below.
And listen out for more updates on the digital Non-Small Cell Lung Cancer Drug Development Summit!
Contact
General Enquiries & Registration Assistance
George O’Connor
Delegate Acquisition Manager
Hanson Wade
(+1) 617 455 4188
info@hansonwade.com
Partnership Opportunities
Adam Mayar
Partnerships Director
Hanson Wade
(+1) 617 455 4188
sponsor@hansonwade.com